Literature DB >> 21212241

Role of Rho-kinase signaling and endothelial dysfunction in modulating blood flow distribution in pulmonary hypertension.

Daryl O Schwenke1, James T Pearson, Takashi Sonobe, Hatsue Ishibashi-Ueda, Akito Shimouchi, Kenji Kangawa, Keiji Umetani, Mikiyasu Shirai.   

Abstract

Rho-kinase-mediated vasoconstriction and endothelial dysfunction are considered two primary instigators of pulmonary arterial hypertension (PAH). However, their contribution to the adverse changes in pulmonary blood flow distribution associated with PAH has not been addressed. This study utilizes synchrotron radiation microangiography to assess the specific role, and contribution of, Rho-kinase-mediated vasoconstriction and endothelial dysfunction in PAH. Male adult Sprague-Dawley rats were injected with saline (Cont-rats) or monocrotaline (MCT-rats) 3 wk before microangiography was performed on the left lung. We assessed dynamic changes in vessel internal diameter (ID) in response to 1) the Rho-kinase inhibitor fasudil (10 mg/kg iv); or 2) ACh (3 μg · kg⁻¹ · min⁻¹), sodium nitroprusside (SNP, 5 μg · kg⁻¹ · min⁻¹), and N(ω)-nitro-l-arginine methyl ester (l-NAME, 50 mg/kg iv). We observed that MCT-rats had fewer vessels of the microcirculation compared with Cont-rats. The fundamental result of this study is that fasudil improved pulmonary blood flow distribution and reduced pulmonary pressure in PAH rats, not only by dilating already-perfused vessels (ID > 100 μm), but also by restoring blood flow to vessels that had previously been constricted closed (ID < 100 μm). Endothelium-dependent vasodilation was impaired in MCT-rats primarily in vessels with an ID < 200 μm. Moreover the vasoconstrictor response to l-NAME was accentuated in MCT-rats, but only in the 200- to 300-μm vessels. These results highlight the importance of Rho-kinase-mediated control and endothelial control of pulmonary vascular tone in PAH. Indeed, an effective therapeutic strategy for treating PAH should target both the smooth muscle Rho-kinase and endothelial pathways.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21212241     DOI: 10.1152/japplphysiol.01318.2010

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  9 in total

Review 1.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

2.  Exogenous ghrelin improves blood flow distribution in pulmonary hypertension-assessed using synchrotron radiation microangiography.

Authors:  Daryl O Schwenke; Emily A Gray; James T Pearson; Takashi Sonobe; Hatsue Ishibashi-Ueda; Isabel Campillo; Kenji Kangawa; Keiji Umetani; Mikiyasu Shirai
Journal:  Pflugers Arch       Date:  2011-07-09       Impact factor: 3.657

3.  Cell permeable peptide conjugated nanoerythrosomes of fasudil prolong pulmonary arterial vasodilation in PAH rats.

Authors:  Nilesh Gupta; Brijeshkumar Patel; Kamrun Nahar; Fakhrul Ahsan
Journal:  Eur J Pharm Biopharm       Date:  2014-11       Impact factor: 5.571

4.  Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.

Authors:  Ioana R Preston; Kristen D Sagliani; Rod R Warburton; Nicholas S Hill; Barry L Fanburg; Iris Z Jaffe
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-03-01       Impact factor: 5.464

5.  Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation.

Authors:  James T Pearson; Mathew J Jenkins; Amanda J Edgley; Takashi Sonobe; Mandar Joshi; Mark T Waddingham; Yutaka Fujii; Daryl O Schwenke; Hirotsugu Tsuchimochi; Misa Yoshimoto; Keiji Umetani; Darren J Kelly; Mikiyasu Shirai
Journal:  Cardiovasc Diabetol       Date:  2013-08-01       Impact factor: 9.951

6.  Hypoxic pulmonary vasoconstriction and vascular contractility in monocrotaline-induced pulmonary arterial hypertensive rats.

Authors:  Hae Jin Kim; Hae Young Yoo
Journal:  Korean J Physiol Pharmacol       Date:  2016-10-28       Impact factor: 2.016

7.  Inhibition of nitric oxide synthase unmasks vigorous vasoconstriction in established pulmonary arterial hypertension.

Authors:  Mariko Tanaka; Kohtaro Abe; Masahiko Oka; Keita Saku; Keimei Yoshida; Tomohito Ishikawa; Ivan F McMurtry; Kenji Sunagawa; Sumio Hoka; Hiroyuki Tsutsui
Journal:  Physiol Rep       Date:  2017-12

8.  Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment.

Authors:  Devashis Mukherjee; Girija G Konduri
Journal:  Compr Physiol       Date:  2021-06-30       Impact factor: 8.915

Review 9.  Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies.

Authors:  Salvatore Rosanio; Francesco Pelliccia; Carlo Gaudio; Cesare Greco; Abdul M Keylani; Darrin C D'Agostino
Journal:  Biomed Res Int       Date:  2014-06-12       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.